Botulinum toxin type a with oral baclofen versus oral tizanidine: A nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity

Journal of Child Neurology

Volumn 23, Issue 12, 2008, Pages 1464-1466

  Dai, Alper I ^a   Wasay, Mohammad ^b   Awan, Safia ^b  

^a GAZIANTEP UNIVERSITY   (Turkey)

^b AGA KHAN UNIVERSITY   (Pakistan)

Author keywords

Baclofen; Botulinum toxin; Cerebral palsy; Tizanidine

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A; TIZANIDINE;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; CEREBRAL PALSY; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; MALE; MOTOR PERFORMANCE; PES EQUINUS; PILOT STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCORING SYSTEM; SPASTICITY; TURKEY (REPUBLIC);

ADMINISTRATION, ORAL; ADOLESCENT; BACLOFEN; BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHI-SQUARE DISTRIBUTION; CHILD; CHILD, PRESCHOOL; CLONIDINE; DRUG THERAPY, COMBINATION; EQUINUS DEFORMITY; FEMALE; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL; NEUROMUSCULAR AGENTS; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 57749198823     PISSN: 08830738     EISSN: None     Source Type: Journal    
DOI: 10.1177/0883073808319074     Document Type: Article

References (15)

1. Kita M., Goodkin DE Drugs used to treat spasticity. Drugs. 2000;59:487-495.
2. Goldstein M., Harper DC Management of cerebral palsy: Equinus gait. Dev Med Child Neurol. 2001;43:563-569.
3. Edgar TS Clinical utility of botulinum toxin in the treatment of cerebral palsy: Comprehensive review. J Child Neurol. 2001;16:37-46.
4. Jefferson RJ Botulinum toxin in the management of cerebral palsy. Dev Med Child Neurol. 2004;46:491-499.
5. Tilton AH Management of spasticity in children with cerebral palsy. Semin Pediatr Neurol. 2004;3:58-65.
6. Al-Shahrani A. Anti-spasticity medications. Saudi Med J. 2003;24:19-22.
7. Koman LA, Smith BP, Shilt JS Cerebral palsy. Lancet. 2004;363:1619-1631.
8. Graham HK, Aoki KR, Autti-Ramo I., et al. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait Posture. 2000;11:67-79.
9. Ljungman G., Kreuger A., Andreasson S., et al. Midazolam nasal spray reduces procedural anxiety in children. Pediatrics. 2000;105:73-78.
10. Patel DR, Soyode O. Pharmacologic interventions for reducing spasticity in cerebral palsy. Indian J Pediatr. 2005;72:869-872.
11. Albright AL Baclofen in the treatment of cerebral palsy. J Child Neurol. 1996;11:77-83.
12. Schneider JW, Gurucharri AL, Gaebler-Spira DJ Health-related quality of life and functional outcome measures for children with cerebral palsy. Dev Med Child Neurol. 2001;43:601-608.
13. Russell DJ, Rosenbaum PL, Avery LM, Lane M. Gross Motor Function Measure (GMFM-66 and GMFM-88) User's Manual. London, England: Mac Keith Press; 2002:326-335.
14. Hsieh JT, Wolfe DL, Miller WC, Curt A.; the SCIRE Research Team. Spasticity outcome measures in spinal cord injury: Psychometric properties and clinical utility. Spinal Cord. 2008;46:86-95.
15. Cardosa ES, Rodrigues BM, Barroso M., et al. Botulinum toxin type A for the treatment of the spastic equinus foot in cerebral palsy. Pediatr Neruol. 2006;34:106-109.